Schneiderman Prelims Vol-I. qxd

HYPERPIGMENTATION, DIFFUSE
AUTOIMMUNE DISEASES, AND DISEASES
OF IMMUNE DYSFUNCTION
Dermatomyositis 
Rook p.1782, 1998, Sixth Edition
Graft vs. host reaction, chronic 
AD 134:602–612, 1998
Lupus erythematosus, systemic 
Rook p.1782, 1998,
Sixth Edition
Morphea – generalized morphea – diffuse hyperpigmentation
Rook p.2511, 1998, Sixth Edition
Pemphigus foliaceus
Rheumatoid arthritis 
Rook p.1782, 1998, Sixth Edition
Scleroderma (progressive systemic sclerosis) – diffuse
cutaneous form; CREST syndrome, morphea 
Rook p.1782,
2527, 1998, Sixth Edition
Still’s disease 
Rook p.1782, 1998, Sixth Edition
CONGENITAL GENERALIZED
HYPERPIGMENTATION
Carbon baby syndrome – universal acquired melanosis – entire
skin deep black 
Textbook of Neonatal Dermatology, p.381,
2001; AD 114:775–778, 1978
Congenital adrenal hyperplasia – congenital generalized
hyperpigmentation 
JAAD 33:323–326, 1995
Congenital diffuse pigmentation (Wende–Bauckus) 
Epidermal melanocytosis 
AD 86:412–418, 1962
Familial pigmentation with nail dystrophy 
AD 71:591–598, 1955
Familial progressive hyperpigmentation 
AD 103:581–8, 1971
Green baby – due to intrauterine exposure to Evan’s blue dye
Am J Perinatol 5:234–235, 1988
DRUG-INDUCED
Cutis 59:77, 1977
ACTH administration 
Rook p.1780, 1998, Sixth Edition
Adriamycin
Amiodarone 
Bolognia p.980, 2003
Argyria – slate-gray pigmentation of sun-exposed areas
(forehead, nose, hands); entire skin may be hyperpigmented
NEJM 351:2349–2350, 2004; Am J Kidney Dis 37:1048–1051,
2001; BJD 104:19–26, 1981; AD 114:373–377, 1978
Arsenic – brown diffuse macular hyperpigmentation 
Ghatan
p.231, 2002, Second Edition
Atabrine (mepacrine) – greenish–yellow pigmentation of face,
hands, feet; then diffuse 
Am J Med Sci 192:645–650, 1936
Bismuth – generalized hyperpigmentation resembling argyria
and/or blue–black line at the gingival margin 
JAAD 39:524–525,
1998; JAAD 37:489–490, 1997
Bleomycin 
AD 107:553–555, 1973
Busulfan – diffuse 
JAAD 9:645–663, 1983; Addisonian Arch Int
Med 124:66–71, 1969
Chemotherapy 
JAAD 40:367–398, 1999
Chloramphenicol overdose in infants – gray baby syndrome
Clin Pediatr 21:571–572, 1982
Chloroquine 
Ghatan p.6, 2002, Second Edition
Chlorpromazine
Chrysiasis
Clofazimine – orange–red hyperpigmentation 
JAAD
23:236–241, 1990
Cyclophosphamide 
Bolognia p.978, 2003
Dactinomycin 
Bolognia p.978, 2003
Daunorubicin 
JAAD 46:S1–3, 2002; JAAD 26:255–256, 1992
5-fluorouracil
Hydantoin
Hydroxychloroquine
Hydroxyurea 
JAAD 49:339–341, 2003; AD 135:818–820, 1999;
JAAD 36:178–182, 1997; AD 111:183–187, 1975
Immunosuppressive therapy in transplant recipients – diffuse
hyperpigmented xerotic dermatitis 
JAAD 44:932–939, 2001
Lichenoid drug eruption
Methotrexate
Minocycline – diffuse hyperpigmentation 
Arthr Rheum
50:3698–3701, 2004; JAAD 3:244–247, 1980
MSH administration 
Ghatan p.6, 2002, Second Edition
Nitrogen mustard, topical 
AD 113:1387–1389, 1977
Oral contraceptives
Phenolphthalein – diffuse brown pigmentation (fixed drug) 
Arch
Dermatol Syphilol 32:915–921, 1935
Phenothazines, including chlorpromazine 
AD 90:471–476, 1964
Phototoxic and photodynamic drug reactions 
Rook p.1787,
1998, Sixth Edition; AD 106–148, 1972
Psoralens (PUVA) 
Quinidine 
AD 122:1062–1064, 1986
Quinine 
AD 88:419–426, 1963
Rifabutin
Silver sulfadiazine cream 
JAAD 12:1112–1114, 1985
Tetracosactrin 
BJD 82:389–396, 1970
Zidovudine 
JAAD 46:284–293, 2002